Canada signs deal with Novovax to get 76 million doses of COVID-19 vaccine
OTTAWA -- The federal government has a deal with a third vaccine developer to get access to an experimental COVID-19 vaccine as early as next spring.
Prime Minister Justin Trudeau is in Montreal this morning where he is set to announce details of the agreement with Maryland-based biotechnology company Novovax.
The contract promises to secure for Canadians 76 million doses of Novovax's vaccine, which is currently in preliminary trials in the United States and Australia.
That would be enough to deliver two doses to almost every Canadian.
This is the third such deal Canada has made with COVID-19 vaccine developers, adding Novovax to similar arrangements made with Pfizer and Moderna earlier this month.
All vaccines remain in clinical trials and must first be deemed safe by the developers and then approved by Health Canada for use here before any Canadians will be vaccinated.
- Canadian-made COVID-19 vaccine approved for clinical trials by Health Canada
- First doses of Pfizer COVID-19 vaccine, not yet approved, to land in Canada next week
- Canada signs deals with two suppliers for potential COVID-19 vaccines
- Moderna chairman says Canada near head of line for 20 million vaccine doses
- Feds on track to have enough doses of COVID-19 vaccine for eligible Canadians
- Mississauga, Brampton services will be affected by new federal holiday in September
- Boy dies after suffering medical episode while playing basketball in Milton
- Large Mississauga complex used by Bell sold in billion dollar deal
- You will now be rewarded for licencing your pet in Hamilton
- Mississauga man facing charges after 7-month-old puppy dragged beside car